Literature DB >> 27354597

Enhanced TLR4 Expression on Colon Cancer Cells After Chemotherapy Promotes Cell Survival and Epithelial-Mesenchymal Transition Through Phosphorylation of GSK3β.

Yoon Hee Chung1, Daejin Kim2.   

Abstract

BACKGROUND: Phosphorylation of glycogen synthase kinase 3β (GSK3β) by phosphatidyl-inositide 3-kinase (PI3K)/protein kinase B (AKT) or inhibition of GSK3β with small-molecule inhibitor attenuates cell survival and proliferation and increases apoptosis in most cancer cell lines. In this study, we investigated the role of phosphorylated GSK3β activated by enhanced toll-like receptor 4 (TLR4) expression in drug-treated colon cancer cells as a model of post-chemotherapy cancer cells.
MATERIALS AND METHODS: The effect of TLR4 stimulation on metastasis and apoptosis in drug-exposed colon cancer cells was determined by real-time polymerase chain reaction (PCR) and immunoblotting.
RESULTS: Despite the induction of apoptosis after treatment with oxaliplatin and 5-fluorouracil, lipopolysaccharide (LPS) stimulation via increased TLR4 in drug-treated cancer cells effectively inhibited apoptosis through up-regulation of expression of anti-apoptosis-related B-cell lymphoma 2 (BCL2) family proteins [X-linked inhibitor of apoptosis protein (XIAP), BCL2, and survivin] and drug-resistance proteins [multidrug-resistance protein 1 (MDR1), multidrug resistance-associated protein (MRP)1/2/3]. LPS-mediated signaling in drug-treated cancer cells elevated the expression of phosphorylated GSK3β, extracellular signal-regulated kinase (ERK), and the p65 subunit of nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). Pharmacological inhibition of GSK3β (using SB216763) reduced phosphorylation of GSK3β, re-activated caspase-dependent apoptosis, and blocked the expression of cancer stem cell markers and invasive characteristics in LPS-stimulated drug-treated cells. In addition, the ERK-specific inhibitor, PD98059, triggered the apoptosis of TLR4-activated drug-exposed colon cancer cells, whereas there was no effect on the expression of epithelial-mesenchymal transition markers or GSK3β phosphorylation.
CONCLUSION: These results suggest that TLR4-induced GSK3β and ERK phosphorylation independently controls cancer cell survival and regulation of GSK3β and ERK after chemotherapy, making TLR4 a critical target for reducing drug resistance and metastasis in patients with colon cancer. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  EMT; GSK-3β; TLR4; colorectal cancer; epithelial–mesenchymal transition

Mesh:

Substances:

Year:  2016        PMID: 27354597

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

Review 1.  Gut microbiota modulation of chemotherapy efficacy and toxicity.

Authors:  James L Alexander; Ian D Wilson; Julian Teare; Julian R Marchesi; Jeremy K Nicholson; James M Kinross
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-03-08       Impact factor: 46.802

2.  Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers.

Authors:  Bahareh Kashani; Zahra Zandi; Mohammad Reza Karimzadeh; Davood Bashash; Ali Nasrollahzadeh; Seyed H Ghaffari
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

3.  The impact of exogenous CO releasing molecule CORM-2 on inflammation and signaling of orthotopic lung cancer.

Authors:  Li Shao; Congyang Liu; Shuhua Wang; Jiannan Liu; Li Wang; Liping Lv; Yong Zou
Journal:  Oncol Lett       Date:  2018-06-26       Impact factor: 2.967

4.  The TLR4-Active Morphine Metabolite Morphine-3-Glucuronide Does Not Elicit Macrophage Classical Activation In Vitro.

Authors:  Samira Khabbazi; Nan Xie; Wenjun Pu; Yannick Goumon; Marie-Odile Parat
Journal:  Front Pharmacol       Date:  2016-11-17       Impact factor: 5.810

5.  Butyrate upregulates the TLR4 expression and the phosphorylation of MAPKs and NK-κB in colon cancer cell in vitro.

Authors:  Tengfei Xiao; Shuiyun Wu; Cheng Yan; Chuanxiang Zhao; Huimin Jin; Nannan Yan; Jie Xu; Yi Wu; Ci Li; Qixiang Shao; Sheng Xia
Journal:  Oncol Lett       Date:  2018-07-24       Impact factor: 2.967

6.  TLR4 expression correlated with PD-L1 expression indicates a poor prognosis in patients with peripheral T-cell lymphomas.

Authors:  Shu Zhao; Mengqi Sun; Hongxue Meng; Hongfei Ji; Yupeng Liu; Minghui Zhang; Hongbin Li; Pengfei Li; Yue Zhang; Qingyuan Zhang
Journal:  Cancer Manag Res       Date:  2019-05-23       Impact factor: 3.989

7.  Herbal melanin inhibits colorectal cancer cell proliferation by altering redox balance, inducing apoptosis, and modulating MAPK signaling.

Authors:  Omar Al-Obeed; Adila Salih El-Obeid; Sabine Matou-Nasri; Mansoor-Ali Vaali-Mohammed; Yazeid AlHaidan; Mohammed Elwatidy; Hamad Al Dosary; Zeyad Alehaideb; Khayal Alkhayal; Adil Haseeb; James McKerrow; Rehan Ahmad; Maha-Hamadien Abdulla
Journal:  Cancer Cell Int       Date:  2020-04-16       Impact factor: 5.722

8.  Dysregulation of TLR2 Serves as a Prognostic Biomarker in Breast Cancer and Predicts Resistance to Endocrine Therapy in the Luminal B Subtype.

Authors:  Yunmei Wang; Shuguang Liu; Yanjun Zhang; Jin Yang
Journal:  Front Oncol       Date:  2020-04-30       Impact factor: 6.244

9.  Prognostic Significance of TLR2, SMAD3 and Localization-dependent SATB1 in Stage I and II Non-Small-Cell Lung Cancer Patients.

Authors:  Justyna Durślewicz; Anna Klimaszewska-Wiśniewska; Jakub Jóźwicki; Paulina Antosik; Marta Smolińska-Świtała; Maciej Gagat; Adam Kowalewski; Dariusz Grzanka
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

Review 10.  Toll-like receptors (TLRs): An old family of immune receptors with a new face in cancer pathogenesis.

Authors:  Yazdan Mokhtari; Atieh Pourbagheri-Sigaroodi; Parisa Zafari; Nader Bagheri; Seyed H Ghaffari; Davood Bashash
Journal:  J Cell Mol Med       Date:  2020-12-18       Impact factor: 5.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.